



1642

PATENT
ATTORNEY DOCKET NUMBER: 50125/044001

#14

Certificate of Mailing: Date of Deposit: March 6, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Colleen Coyne
Printed name of person mailing correspondence

Colleen Coyne
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: Michael Hallek et al.

Art Unit:

MAR 13 2003

Serial No.: 10/031,313

Examiner:

TECH CENTER 1600/2900

Filed: June 3, 2002

Customer No.: 21559

Title: STRUCTURAL PROTEIN OF ADENO-ASSOCIATED VIRUS
WITH MODIFIED ANTIGENICITY, ITS PRODUCTION AND ITS
USE

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 4 March 2003



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No. 50125/044001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No. 10/031,313		RECEIVED MAR 13 2003
(37 C.F.R. § 1.98(b))		Applicant Hallek et al.		June 3, 2002
		Filing Date 1642		TECH CENTER 1600/2900
		Group		March 6, 2003
		IDS Filed		

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/67393	12/29/99	PCT			
	WO 97/38723	10/23/97	PCT			
	WO 96/00587	01/11/96	PCT			
	WO 95/23867	09/08/95	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Aumailley et al., "Identification of the Arg-Gly-Asp Sequence in Laminin A Chain as a Latent Cell-Binding Site Being Exposed in Fragment P1," <i>FEBS</i> 262:82-86 (1990).
	Bartlett et al., "Targeted Adeno-Associated Virus Vector Transduction of Nonpermissive Cells Mediated by a Bispecific F (ab') ₂ Antibody," <i>Nature Biotechnology</i> 17:181-186 (1999).
	Chapman et al., "Structure, Sequence, and Function Correlations Among Parvoviruses," <i>Virology</i> 194:491-508 (1993).
	Chiorini et al., "High-Efficiency Transfer of the T Cell Co-Stimulatory Molecular B7-2 to Lymphoid Cells Using High-Titer Recombinant Adeno-Associated Virus Vectors," <i>Human Gene Therapy</i> 6:1531-1541 (1995).
	Cosset et al., "Targeting Retrovirus Entry," <i>Gene Therapy</i> 3:946-956 (1996).
	Douglas et al., "Targeted Gene Delivery by Tropism-Modified Adenoviral Vectors," <i>Nature Biotechnology</i> 14:1574-1578 (1996).
	Girod et al., "Genetic Capsid Modifications Allow Efficient Re-Targeting of Adeno-Associated Virus Type 2," <i>Nature Medicine</i> 5:1052-1056 (1999).
	Hermonat et al., "Genetics of Adeno-Associated Virus: Isolation and Preliminary Characterization of Adeno-Associated Virus Type 2 Mutants," <i>Journal of Virology</i> 51:329-339 (1984).
	Luo et al., "Preliminary X-Ray Crystallographic Analysis of Canine Parovirus Crystals," <i>J. Mol. Biol.</i> 200:209-211 (1988).
	Kotin, "Prospects for the Use of Adeno-Associated Virus as a Vector For Human Gene Therapy," <i>Human Gene Therapy</i> 5:793-801 (1994).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

50125/044901

Serial No.

10/031,313

Applicant

Hallek et al.

Filing Date

June 3, 2002

Group

1642

IDS Filed

March 6, 2003

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

37 C.F.R. § 1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

Krasnykh et al., "Generation of Recombinant Adenovirus Vectors With Modified Fibers for Altering Viral Tropism," *Journal of Virology* 70:6839-6846 (1996).Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," *Current Topics in Microbiology and Immunology* 158:97-129 (1992).Nimako et al., "Human Papillomavirus-Specific Cytotoxic T Lymphocytes in Patients with Cervical Intraepithelial Neoplasia Grade III," *Cancer Research* 57:4855-4861 (1997).Ohno et al., "Cell-Specific Targeting of Sindbis Virus Vectors Displaying IgG-Binding Domains of Protein A," *Nature Biotechnology* 15:763-767 (1997).Ruffing et al., "Mutations in the Carboxy Terminus of Adeno-Associated Virus 2 Capsid Proteins Affect Viral Infectivity: Lack of an RGD Integrin-Binding Motif," *Journal of General Virology* 75:3385-3392 (1994).Ruffing et al., "Assembly of Viruslike Particles by Recombinant Structural Proteins of Adeno-Associated Virus Type 2 in Insect Cells," *Journal of Virology* 66:6922-6930 (1992).Rutledge et al., "Infectious Clones and Vectors Derived from Adeno-Associated Virus (AAV) Serotypes Other Than AAV Type 2," *Journal of Virology* 72:309-319 (1998).Steinbach et al., "Assembly of Adeno-Associated Virus Type 2 Capsids in vitro," *Journal of General Virology* 78:1453-1462 (1997) (Abstract).Stevenson et al., "Selective Targeting Human Cells by a Chimeric Adenovirus Vector Containing a Modified Fiber Protein," *Journal of Virology* 71:4782-4790 (1997).Srivastava et al., "Nucleotide Sequence and Organization of the Adeno-Associated Virus 2 Genome," *Journal of Virology* 45:555-564 (1983).Tarpey et al., "Human Cytotoxic T Lymphocytes Stimulated by Endogenously Processed Human Papillomavirus Type 11 E7 Recognize a Peptide Containing a HLA-A2 (A*0201) Motif," *Immunology* 81:222-227 (1994).Tsao et al., "The Three-Dimensional Structure of Canine Parvovirus and Its Functional Implications," *Science* 251:1456-1464 (1991).Valsesia-Wittmann et al., "Modifications in the Binding Domain of Avian Retrovirus Envelope Protein to Redirect the Host Range of Retroviral Vectors," *Journal of Virology* 68:4609-4619 (1994).Wickham et al., "Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Proteins," *Journal of Virology* 71:8221-8229 (1997).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

SUBSTITUTE FORM PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Attorney Docket No.

501257/42001

Serial No.

10/031,313

Applicant

Hallek et al.

Filing Date

June 3, 2002

Group

1642

IDS Filed

March 6, 2003

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 C.F.R. § 1.98(b))

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Wistuba et al., "Subcellular Compartmentalization of Adeno-Associated Virus Type 2 Assembly," <i>Journal of Virology</i> 71:1341-1352 (1997).
	Wistuba et al., "Intermediates of Adeno-Associated Virus Type 2 Assembly: Identification of Soluble Complexes Containing Rep and Cap Proteins," <i>Journal of Virology</i> 69:5311-5319 (1995).
	Wu et al., "The Canine Parvovirus Empty Capsid Structure," <i>J. Mol. Biol.</i> 233:231-244 (1993).
	Yang et al., "Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy," <i>Human Gene Therapy</i> 9:1929-1937 (1998).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.